Kanellis D, Espinoza J, Zisi A, Sakkas E, Bartkova J, Katsori A, et al. The exon-junction complex helicase eIF4A3 controls cell fate via coordinated regulation of ribosome biogenesis and translational output. Sci Adv. 2021;7: pubmed publisher

Loureiro J, Raimundo L, Calheiros J, Carvalho C, Barcherini V, Lima N, et al. Targeting p53 for Melanoma Treatment: Counteracting Tumour Proliferation, Dissemination and Therapeutic Resistance. Cancers (Basel). 2021;13: pubmed publisher

Gao L, Zhu D, Wang Q, Bao Z, Yin S, Qiang H, et al. Proteome Analysis of USP7 Substrates Revealed Its Role in Melanoma Through PI3K/Akt/FOXO and AMPK Pathways. Front Oncol. 2021;11:650165 pubmed publisher

Li H, Liu Y, Jiang W, Xue J, Cheng Y, Wang J, et al. Icaritin promotes apoptosis and inhibits proliferation by down-regulating AFP gene expression in hepatocellular carcinoma. BMC Cancer. 2021;21:318 pubmed publisher

Sola M, Magrin C, Pedrioli G, Pinton S, Salvade A, Papin S, et al. Tau affects P53 function and cell fate during the DNA damage response. Commun Biol. 2020;3:245 pubmed publisher

Gain C, Malik S, Bhattacharjee S, Ghosh A, Robertson E, Das B, et al. Proteasomal inhibition triggers viral oncoprotein degradation via autophagy-lysosomal pathway. PLoS Pathog. 2020;16:e1008105 pubmed publisher

Du T, Li H, Fan Y, Yuan L, Guo X, Zhu Q, et al. The deubiquitylase OTUD3 stabilizes GRP78 and promotes lung tumorigenesis. Nat Commun. 2019;10:2914 pubmed publisher

Carugo A, Minelli R, Sapio L, Soeung M, Carbone F, Robinson F, et al. p53 Is a Master Regulator of Proteostasis in SMARCB1-Deficient Malignant Rhabdoid Tumors. Cancer Cell. 2019;35:204-220.e9 pubmed publisher

Kim M, Song J, Koh D, Kim J, Hatano M, Jeon B, et al. Reciprocal negative regulation between the tumor suppressor protein p53 and B cell CLL/lymphoma 6 (BCL6) via control of caspase-1 expression. J Biol Chem. 2019;294:299-313 pubmed publisher

Tajan M, Hock A, Blagih J, Robertson N, Labuschagne C, Kruiswijk F, et al. A Role for p53 in the Adaptation to Glutamine Starvation through the Expression of SLC1A3. Cell Metab. 2018;28:721-736.e6 pubmed publisher

Klein M, Dickson M, Antonescu C, Qin L, Dooley S, Barlas A, et al. PDLIM7 and CDH18 regulate the turnover of MDM2 during CDK4/6 inhibitor therapy-induced senescence. Oncogene. 2018;37:5066-5078 pubmed publisher

Parisotto M, Grelet E, El Bizri R, Dai Y, Terzic J, Eckert D, et al. PTEN deletion in luminal cells of mature prostate induces replication stress and senescence in vivo. J Exp Med. 2018;215:1749-1763 pubmed publisher

Huang C, Wu S, Ji H, Yan X, Xie Y, Murai S, et al. Identification of XBP1-u as a novel regulator of the MDM2/p53 axis using an shRNA library. Sci Adv. 2017;3:e1701383 pubmed publisher

Giono L, Resnick Silverman L, Carvajal L, St Clair S, Manfredi J. Mdm2 promotes Cdc25C protein degradation and delays cell cycle progression through the G2/M phase. Oncogene. 2017;36:6762-6773 pubmed publisher

Lee T, Pelletier J. Dependence of p53-deficient cells on the DHX9 DExH-box helicase. Oncotarget. 2017;8:30908-30921 pubmed publisher

Zhang Y, Zeng S, Hao Q, Lu H. Monitoring p53 by MDM2 and MDMX is required for endocrine pancreas development and function in a spatio-temporal manner. Dev Biol. 2017;423:34-45 pubmed publisher

Squillaro T, Antonucci I, Alessio N, Esposito A, Cipollaro M, Melone M, et al. Impact of lysosomal storage disorders on biology of mesenchymal stem cells: Evidences from in vitro silencing of glucocerebrosidase (GBA) and alpha-galactosidase A (GLA) enzymes. J Cell Physiol. 2017;232:3454-3467 pubmed publisher

Guan X, Lapak K, Hennessey R, Yu C, Shakya R, Zhang J, et al. Stromal Senescence By Prolonged CDK4/6 Inhibition Potentiates Tumor Growth. Mol Cancer Res. 2017;15:237-249 pubmed publisher

Qi D, Cobrinik D. MDM2 but not MDM4 promotes retinoblastoma cell proliferation through p53-independent regulation of MYCN translation. Oncogene. 2017;36:1760-1769 pubmed publisher

Clay M, Martinez A, Weiss S, Edgar M. MDM2 and CDK4 Immunohistochemistry: Should It Be Used in Problematic Differentiated Lipomatous Tumors?: A New Perspective. Am J Surg Pathol. 2016;40:1647-1652 pubmed

Riascos Bernal D, Chinnasamy P, Cao L, Dunaway C, Valenta T, Basler K, et al. β-Catenin C-terminal signals suppress p53 and are essential for artery formation. Nat Commun. 2016;7:12389 pubmed publisher

Ma T, Fan B, Zhang C, Zhao H, Han C, Gao C, et al. Metabonomics applied in exploring the antitumour mechanism of physapubenolide on hepatocellular carcinoma cells by targeting glycolysis through the Akt-p53 pathway. Sci Rep. 2016;6:29926 pubmed publisher

York D, Withers S, Watson K, Seo K, Rebhun R. Enrofloxacin enhances the effects of chemotherapy in canine osteosarcoma cells with mutant and wild-type p53. Vet Comp Oncol. 2017;15:1087-1100 pubmed publisher

Chesnokova V, Zonis S, Zhou C, Recouvreux M, Ben Shlomo A, Araki T, et al. Growth hormone is permissive for neoplastic colon growth. Proc Natl Acad Sci U S A. 2016;113:E3250-9 pubmed publisher

Chen Y, Pan K, Wang P, Cao Z, Wang W, Wang S, et al. HBP1-mediated Regulation of p21 Protein through the Mdm2/p53 and TCF4/EZH2 Pathways and Its Impact on Cell Senescence and Tumorigenesis. J Biol Chem. 2016;291:12688-705 pubmed publisher

Hall A, Lu W, Godfrey J, Antonov A, Paicu C, Moxon S, et al. The cytoskeleton adaptor protein ankyrin-1 is upregulated by p53 following DNA damage and alters cell migration. Cell Death Dis. 2016;7:e2184 pubmed publisher

Jin H, Lee K, Kim Y, Oh H, Maeng Y, Kim T, et al. Scaffold protein FHL2 facilitates MDM2-mediated degradation of IER3 to regulate proliferation of cervical cancer cells. Oncogene. 2016;35:5106-18 pubmed publisher

Chen S, FORRESTER W, Lahav G. Schedule-dependent interaction between anticancer treatments. Science. 2016;351:1204-8 pubmed publisher

Nakayama R, Zhang Y, Czaplinski J, Anatone A, Sicinska E, Fletcher J, et al. Preclinical activity of selinexor, an inhibitor of XPO1, in sarcoma. Oncotarget. 2016;7:16581-92 pubmed publisher

Swetzig W, Wang J, Das G. Estrogen receptor alpha (ERα/ESR1) mediates the p53-independent overexpression of MDM4/MDMX and MDM2 in human breast cancer. Oncotarget. 2016;7:16049-69 pubmed publisher

Liu X, Tan Y, Zhang C, Zhang Y, Zhang L, Ren P, et al. NAT10 regulates p53 activation through acetylating p53 at K120 and ubiquitinating Mdm2. EMBO Rep. 2016;17:349-66 pubmed publisher

Chavoshi S, Egorova O, Lacdao I, Farhadi S, Sheng Y, Saridakis V. Identification of Kaposi Sarcoma Herpesvirus (KSHV) vIRF1 Protein as a Novel Interaction Partner of Human Deubiquitinase USP7. J Biol Chem. 2016;291:6281-91 pubmed publisher

Ying M, Zhang L, Zhou Q, Shao X, Cao J, Zhang N, et al. The E3 ubiquitin protein ligase MDM2 dictates all-trans retinoic acid-induced osteoblastic differentiation of osteosarcoma cells by modulating the degradation of RARα. Oncogene. 2016;35:4358-67 pubmed publisher

Daniele S, Barresi E, Zappelli E, Marinelli L, Novellino E, Da Settimo F, et al. Long lasting MDM2/Translocator protein modulator: a new strategy for irreversible apoptosis of human glioblastoma cells. Oncotarget. 2016;7:7866-84 pubmed publisher

Dewaele M, Tabaglio T, Willekens K, Bezzi M, Teo S, Low D, et al. Antisense oligonucleotide-mediated MDM4 exon 6 skipping impairs tumor growth. J Clin Invest. 2016;126:68-84 pubmed publisher

Ivanschitz L, Takahashi Y, Jollivet F, Ayrault O, Le Bras M, de Thé H. PML IV/ARF interaction enhances p53 SUMO-1 conjugation, activation, and senescence. Proc Natl Acad Sci U S A. 2015;112:14278-83 pubmed publisher

Waye S, Naeem A, Choudhry M, Parasido E, Tricoli L, Sivakumar A, et al. The p53 tumor suppressor protein protects against chemotherapeutic stress and apoptosis in human medulloblastoma cells. Aging (Albany NY). 2015;7:854-68 pubmed

Ahn H, Kim K, Shin K, Lim K, Kim J, Lee J, et al. Ell3 stabilizes p53 following CDDP treatment via its effects on ubiquitin-dependent and -independent proteasomal degradation pathways in breast cancer cells. Oncotarget. 2015;6:44523-37 pubmed publisher

Yu Z, Huang Y, Shieh S. Requirement for human Mps1/TTK in oxidative DNA damage repair and cell survival through MDM2 phosphorylation. Nucleic Acids Res. 2016;44:1133-50 pubmed publisher

Tonsing Carter E, Bailey B, Saadatzadeh M, Ding J, Wang H, Sinn A, et al. Potentiation of Carboplatin-Mediated DNA Damage by the Mdm2 Modulator Nutlin-3a in a Humanized Orthotopic Breast-to-Lung Metastatic Model. Mol Cancer Ther. 2015;14:2850-63 pubmed publisher

Ye M, Tang Y, Tang S, Liu J, Wu K, Yao S, et al. STIP is a critical nuclear scaffolding protein linking USP7 to p53-Mdm2 pathway regulation. Oncotarget. 2015;6:34718-31 pubmed publisher

Moussa R, Kovacevic Z, Richardson D. Differential targeting of the cyclin-dependent kinase inhibitor, p21CIP1/WAF1, by chelators with anti-proliferative activity in a range of tumor cell-types. Oncotarget. 2015;6:29694-711 pubmed publisher

Wang H, Lööf S, Borg P, Nader G, Blau H, Simon A. Turning terminally differentiated skeletal muscle cells into regenerative progenitors. Nat Commun. 2015;6:7916 pubmed publisher

Haupt S, Buckley D, Pang J, Panimaya J, Paul P, Gamell C, et al. Targeting Mdmx to treat breast cancers with wild-type p53. Cell Death Dis. 2015;6:e1821 pubmed publisher

Rueda Rincon N, Bloch K, Derua R, Vyas R, Harms A, Hankemeier T, et al. p53 attenuates AKT signaling by modulating membrane phospholipid composition. Oncotarget. 2015;6:21240-54 pubmed

Wu H, Leng R. MDM2 mediates p73 ubiquitination: a new molecular mechanism for suppression of p73 function. Oncotarget. 2015;6:21479-92 pubmed

Scala F, Brighenti E, Govoni M, Imbrogno E, Fornari F, Treré D, et al. Direct relationship between the level of p53 stabilization induced by rRNA synthesis-inhibiting drugs and the cell ribosome biogenesis rate. Oncogene. 2016;35:977-89 pubmed publisher

Kovatcheva M, Liu D, Dickson M, Klein M, O Connor R, Wilder F, et al. MDM2 turnover and expression of ATRX determine the choice between quiescence and senescence in response to CDK4 inhibition. Oncotarget. 2015;6:8226-43 pubmed

Kong L, Wei J, Haider A, Liebelt B, Ling X, Conrad C, et al. Therapeutic targets in subependymoma. J Neuroimmunol. 2014;277:168-75 pubmed publisher

Giovannini C, Minguzzi M, Baglioni M, Fornari F, Giannone F, Ravaioli M, et al. Suppression of p53 by Notch3 is mediated by Cyclin G1 and sustained by MDM2 and miR-221 axis in hepatocellular carcinoma. Oncotarget. 2014;5:10607-20 pubmed

Vega Naredo I, Cunha Oliveira T, Serafim T, Sardao V, Oliveira P. Analysis of pro-apoptotic protein trafficking to and from mitochondria. Methods Mol Biol. 2015;1241:163-80 pubmed publisher

Lee M, Marina M, King J, Saavedra H. Differential expression of centrosome regulators in Her2+ breast cancer cells versus non-tumorigenic MCF10A cells. Cell Div. 2014;9:3 pubmed publisher

Idogawa M, Ohashi T, Sugisaka J, Sasaki Y, Suzuki H, Tokino T. Array-based genome-wide RNAi screening to identify shRNAs that enhance p53-related apoptosis in human cancer cells. Oncotarget. 2014;5:7540-8 pubmed

Jacob A, Singh R, Comiskey D, Rouhier M, Mohammad F, Bebee T, et al. Stress-induced alternative splice forms of MDM2 and MDMX modulate the p53-pathway in distinct ways. PLoS ONE. 2014;9:e104444 pubmed publisher

Suico M, Fukuda R, Miyakita R, Koyama K, Taura M, Shuto T, et al. The transcription factor MEF/Elf4 is dually modulated by p53-MDM2 axis and MEF-MDM2 autoregulatory mechanism. J Biol Chem. 2014;289:26143-54 pubmed publisher

Hamilton G, Abraham A, Morton J, Sampson O, Pefani D, Khoronenkova S, et al. AKT regulates NPM dependent ARF localization and p53mut stability in tumors. Oncotarget. 2014;5:6142-67 pubmed

Yamauchi T, Nishiyama M, Moroishi T, Yumimoto K, Nakayama K. MDM2 mediates nonproteolytic polyubiquitylation of the DEAD-Box RNA helicase DDX24. Mol Cell Biol. 2014;34:3321-40 pubmed publisher

Kardos G, Dai M, Robertson G. Growth inhibitory effects of large subunit ribosomal proteins in melanoma. Pigment Cell Melanoma Res. 2014;27:801-12 pubmed publisher

Thirunavukarasou A, Singh P, Govindarajalu G, Bandi V, Baluchamy S. E3 ubiquitin ligase Cullin4B mediated polyubiquitination of p53 for its degradation. Mol Cell Biochem. 2014;390:93-100 pubmed publisher

Qi M, Zhang J, Zeng W, Chen X. DNAJB1 stabilizes MDM2 and contributes to cancer cell proliferation in a p53-dependent manner. Biochim Biophys Acta. 2014;1839:62-9 pubmed publisher

Horiguchi M, Koyanagi S, Hamdan A, Kakimoto K, Matsunaga N, Yamashita C, et al. Rhythmic control of the ARF-MDM2 pathway by ATF4 underlies circadian accumulation of p53 in malignant cells. Cancer Res. 2013;73:2639-49 pubmed publisher

Kazmi S, Byer S, Eckert J, Turk A, Huijbregts R, Brossier N, et al. Transgenic mice overexpressing neuregulin-1 model neurofibroma-malignant peripheral nerve sheath tumor progression and implicate specific chromosomal copy number variations in tumorigenesis. Am J Pathol. 2013;182:646-67 pubmed publisher

Singh S, Ramamoorthy M, Vaughan C, Yeudall W, Deb S, Palit Deb S. Human oncoprotein MDM2 activates the Akt signaling pathway through an interaction with the repressor element-1 silencing transcription factor conferring a survival advantage to cancer cells. Cell Death Differ. 2013;20:558-66 pubmed publisher

Calabrò V, Mansueto G, Parisi T, Vivo M, Calogero R, La Mantia G. The human MDM2 oncoprotein increases the transcriptional activity and the protein level of the p53 homolog p63. J Biol Chem. 2002;277:2674-81 pubmed

Bellet M, Stincardini C, Costantini C, Gargaro M, Pieroni S, Castelli M, et al. The Circadian Protein PER1 Modulates the Cellular Response to Anticancer Treatments. Int J Mol Sci. 2021;22: pubmed publisher

Videla Richardson G, Furmento V, Garcia C, Morris Hanon O, Sevlever G, Romorini L, et al. Human embryonic stem cells display a pronounced sensitivity to the cyclin dependent kinase inhibitor Roscovitine. BMC Mol Cell Biol. 2019;20:40 pubmed publisher

Thangaraj K, Balasubramanian B, Park S, Natesan K, Liu W, Manju V. Orientin Induces G0/G1 Cell Cycle Arrest and Mitochondria Mediated Intrinsic Apoptosis in Human Colorectal Carcinoma HT29 Cells. Biomolecules. 2019;9: pubmed publisher

Sica V, Bravo San Pedro J, Izzo V, Pol J, Pierredon S, Enot D, et al. Lethal Poisoning of Cancer Cells by Respiratory Chain Inhibition plus Dimethyl α-Ketoglutarate. Cell Rep. 2019;27:820-834.e9 pubmed publisher

Nie X, Zheng J, Ricupero C, He L, Jiao K, Mao J. mTOR acts as a pivotal signaling hub for neural crest cells during craniofacial development. PLoS Genet. 2018;14:e1007491 pubmed publisher

Li Y, Stockton M, Eisinger B, Zhao Y, Miller J, Bhuiyan I, et al. Reducing histone acetylation rescues cognitive deficits in a mouse model of Fragile X syndrome. Nat Commun. 2018;9:2494 pubmed publisher

Qian M, Liu Z, Peng L, Tang X, Meng F, Ao Y, et al. Boosting ATM activity alleviates aging and extends lifespan in a mouse model of progeria. elife. 2018;7: pubmed publisher

Li D, Tavana O, Sun S, Gu W. Peli1 Modulates the Subcellular Localization and Activity of Mdmx. Cancer Res. 2018;78:2897-2910 pubmed publisher

Epanchintsev A, Costanzo F, Rauschendorf M, Caputo M, Ye T, Donnio L, et al. Cockayne's Syndrome A and B Proteins Regulate Transcription Arrest after Genotoxic Stress by Promoting ATF3 Degradation. Mol Cell. 2017;68:1054-1066.e6 pubmed publisher

Todoric J, Antonucci L, Di Caro G, Li N, Wu X, Lytle N, et al. Stress-Activated NRF2-MDM2 Cascade Controls Neoplastic Progression in Pancreas. Cancer Cell. 2017;32:824-839.e8 pubmed publisher

Lamberto I, Liu X, Seo H, Schauer N, Iacob R, Hu W, et al. Structure-Guided Development of a Potent and Selective Non-covalent Active-Site Inhibitor of USP7. Cell Chem Biol. 2017;24:1490-1500.e11 pubmed publisher

Zhuge W, Chen R, Vladimir K, Dong X, Zia K, Sun X, et al. Costunolide specifically binds and inhibits thioredoxin reductase 1 to induce apoptosis in colon cancer. Cancer Lett. 2018;412:46-58 pubmed publisher

Porter J, Fisher B, Baranello L, Liu J, Kambach D, Nie Z, et al. Global Inhibition with Specific Activation: How p53 and MYC Redistribute the Transcriptome in the DNA Double-Strand Break Response. Mol Cell. 2017;67:1013-1025.e9 pubmed publisher

Li Q, Liu X, Jin K, Lu M, Zhang C, Du X, et al. NAT10 is upregulated in hepatocellular carcinoma and enhances mutant p53 activity. BMC Cancer. 2017;17:605 pubmed publisher

Chen Y, Wang D, Wu Y, Su D, Zhou T, Gai R, et al. MDM2 promotes epithelial-mesenchymal transition and metastasis of ovarian cancer SKOV3 cells. Br J Cancer. 2017;117:1192-1201 pubmed publisher

Zheng S, Koh X, Goh H, Rahmat S, Hwang L, Lane D. Inhibiting p53 Acetylation Reduces Cancer Chemotoxicity. Cancer Res. 2017;77:4342-4354 pubmed publisher

Shimazu K, Tada Y, Morinaga T, Shingyoji M, Sekine I, Shimada H, et al. Metformin produces growth inhibitory effects in combination with nutlin-3a on malignant mesothelioma through a cross-talk between mTOR and p53 pathways. BMC Cancer. 2017;17:309 pubmed publisher

McClurg U, Cork D, Darby S, Ryan Munden C, Nakjang S, Mendes Côrtes L, et al. Identification of a novel K311 ubiquitination site critical for androgen receptor transcriptional activity. Nucleic Acids Res. 2017;45:1793-1804 pubmed publisher

López Mateo I, Arruabarrena Aristorena A, Artaza Irigaray C, López J, Calvo E, Belandia B. HEY1 functions are regulated by its phosphorylation at Ser-68. Biosci Rep. 2016;36: pubmed publisher

Schmidt M, Calvisi D, Clark G. NORE1A Regulates MDM2 Via ?-TrCP. Cancers (Basel). 2016;8: pubmed publisher

Sørensen B, Nielsen D, Thorsteinsdottir U, Hoffmann E, Lambert I. Downregulation of LRRC8A protects human ovarian and alveolar carcinoma cells against Cisplatin-induced expression of p53, MDM2, p21Waf1/Cip1, and Caspase-9/-3 activation. Am J Physiol Cell Physiol. 2016;310:C857-73 pubmed publisher

Zhang L, Yang C, Varelas X, Monti S. Altered RNA editing in 3' UTR perturbs microRNA-mediated regulation of oncogenes and tumor-suppressors. Sci Rep. 2016;6:23226 pubmed publisher

Jiang Q, Cheng K, Mei X, Qiu J, Zhang W, Xue Y, et al. Synergistic anticancer effects of triptolide and celastrol, two main compounds from thunder god vine. Oncotarget. 2015;6:32790-804 pubmed publisher

Takei Y, Okamoto S, Kawamura K, Jiang Y, Morinaga T, Shingyoji M, et al. Expression of p53 synergistically augments caspases-mediated apoptosis induced by replication-competent adenoviruses in pancreatic carcinoma cells. Cancer Gene Ther. 2015;22:445-53 pubmed publisher

Hoffman Luca C, Yang C, Lu J, Ziazadeh D, McEachern D, Debussche L, et al. Significant Differences in the Development of Acquired Resistance to the MDM2 Inhibitor SAR405838 between In Vitro and In Vivo Drug Treatment. PLoS ONE. 2015;10:e0128807 pubmed publisher

Aguilar A, Sun W, Liu L, Lu J, McEachern D, Bernard D, et al. Design of chemically stable, potent, and efficacious MDM2 inhibitors that exploit the retro-mannich ring-opening-cyclization reaction mechanism in spiro-oxindoles. J Med Chem. 2014;57:10486-98 pubmed publisher

Huang E, Wang F, Chen Y, Chen Y, Wang C, Lin I, et al. Amifostine alleviates radiation-induced lethal small bowel damage via promotion of 14-3-3σ-mediated nuclear p53 accumulation. Oncotarget. 2014;5:9756-69 pubmed

Wolfe A, Singh K, Zhong Y, Drewe P, Rajasekhar V, Sanghvi V, et al. RNA G-quadruplexes cause eIF4A-dependent oncogene translation in cancer. Nature. 2014;513:65-70 pubmed publisher

Monti P, Ciribilli Y, Bisio A, Foggetti G, Raimondi I, Campomenosi P, et al. ?N-P63? and TA-P63? exhibit intrinsic differences in transactivation specificities that depend on distinct features of DNA target sites. Oncotarget. 2014;5:2116-30 pubmed

Allen M, Andrysik Z, Dengler V, Mellert H, Guarnieri A, Freeman J, et al. Global analysis of p53-regulated transcription identifies its direct targets and unexpected regulatory mechanisms. elife. 2014;3:e02200 pubmed publisher

Daniele S, Taliani S, Da Pozzo E, Giacomelli C, Costa B, Trincavelli M, et al. Apoptosis therapy in cancer: the first single-molecule co-activating p53 and the translocator protein in glioblastoma. Sci Rep. 2014;4:4749 pubmed publisher

Dolfi S, Jäger A, Medina D, Haffty B, Yang J, Hirshfield K. Fulvestrant treatment alters MDM2 protein turnover and sensitivity of human breast carcinoma cells to chemotherapeutic drugs. Cancer Lett. 2014;350:52-60 pubmed publisher

Yu Q, Li Y, Mu K, Li Z, Meng Q, Wu X, et al. Amplification of Mdmx and overexpression of MDM2 contribute to mammary carcinogenesis by substituting for p53 mutations. Diagn Pathol. 2014;9:71 pubmed publisher

Touqan N, Diggle C, Verghese E, Perry S, Horgan K, Merchant W, et al. An observational study on the expression levels of MDM2 and MDMX proteins, and associated effects on P53 in a series of human liposarcomas. BMC Clin Pathol. 2013;13:32 pubmed publisher

Joshi M, Yao N, Myers K, Li Z. Human serum albumin and p53-activating peptide fusion protein is able to promote apoptosis and deliver fatty acid-modified molecules. PLoS ONE. 2013;8:e80926 pubmed publisher

Iwasa H, Kudo T, Maimaiti S, Ikeda M, Maruyama J, Nakagawa K, et al. The RASSF6 tumor suppressor protein regulates apoptosis and the cell cycle via MDM2 protein and p53 protein. J Biol Chem. 2013;288:30320-9 pubmed publisher

Bogazzi F, Raggi F, Russo D, Bohlooly Y M, Sardella C, Urbani C, et al. Growth hormone is necessary for the p53-mediated, obesity-induced insulin resistance in male C57BL/6J x CBA mice. Endocrinology. 2013;154:4226-36 pubmed publisher

Liu Y, Xing R, Zhang X, Dong W, Zhang J, Yan Z, et al. miR-375 targets the p53 gene to regulate cellular response to ionizing radiation and etoposide in gastric cancer cells. DNA Repair (Amst). 2013;12:741-50 pubmed publisher

Chen X, Chen J, Gan S, Guan H, Zhou Y, Ouyang Q, et al. DNA damage strength modulates a bimodal switch of p53 dynamics for cell-fate control. BMC Biol. 2013;11:73 pubmed publisher

Orre L, Panizza E, Kaminskyy V, Vernet E, Gräslund T, Zhivotovsky B, et al. S100A4 interacts with p53 in the nucleus and promotes p53 degradation. Oncogene. 2013;32:5531-40 pubmed publisher

Mosbech A, Lukas C, Bekker Jensen S, Mailand N. The deubiquitylating enzyme USP44 counteracts the DNA double-strand break response mediated by the RNF8 and RNF168 ubiquitin ligases. J Biol Chem. 2013;288:16579-87 pubmed publisher

Fukuda R, Suico M, Koyama K, Omachi K, Kai Y, Matsuyama S, et al. Mild electrical stimulation at 0.1-ms pulse width induces p53 protein phosphorylation and G2 arrest in human epithelial cells. J Biol Chem. 2013;288:16117-26 pubmed publisher

Amir S, Ma A, Shi X, Xue L, Kung H, deVere White R. Oncomir miR-125b suppresses p14(ARF) to modulate p53-dependent and p53-independent apoptosis in prostate cancer. PLoS ONE. 2013;8:e61064 pubmed publisher

Su H, Xu T, Ganapathy S, Shadfan M, Long M, Huang T, et al. Elevated snoRNA biogenesis is essential in breast cancer. Oncogene. 2014;33:1348-58 pubmed publisher

Tao T, Shi H, Guan Y, Huang D, Chen Y, Lane D, et al. Def defines a conserved nucleolar pathway that leads p53 to proteasome-independent degradation. Cell Res. 2013;23:620-34 pubmed publisher

McEvoy J, Ulyanov A, Brennan R, Wu G, Pounds S, Zhang J, et al. Analysis of MDM2 and MDM4 single nucleotide polymorphisms, mRNA splicing and protein expression in retinoblastoma. PLoS ONE. 2012;7:e42739 pubmed publisher

Yang M, Yuan F, Li P, Chen Z, Chen A, Li S, et al. Interferon regulatory factor 4 binding protein is a novel p53 target gene and suppresses cisplatin-induced apoptosis of breast cancer cells. Mol Cancer. 2012;11:54 pubmed

Kudo T, Ikeda M, Nishikawa M, Yang Z, Ohno K, Nakagawa K, et al. The RASSF3 candidate tumor suppressor induces apoptosis and G1-S cell-cycle arrest via p53. Cancer Res. 2012;72:2901-11 pubmed publisher

Reverdy C, Conrath S, Lopez R, Planquette C, Atmanene C, Collura V, et al. Discovery of specific inhibitors of human USP7/HAUSP deubiquitinating enzyme. Chem Biol. 2012;19:467-77 pubmed publisher

Lamprecht B, Kreher S, Möbs M, Sterry W, Dorken B, Janz M, et al. The tumour suppressor p53 is frequently nonfunctional in Sézary syndrome. Br J Dermatol. 2012;167:240-6 pubmed publisher

Takahashi A, Tokita H, Takahashi K, Takeoka T, Murayama K, Tomotsune D, et al. A novel potent tumour promoter aberrantly overexpressed in most human cancers. Sci Rep. 2011;1:15 pubmed publisher

Sarkar T, Sharan S, Wang J, Pawar S, Cantwell C, Johnson P, et al. Identification of a Src tyrosine kinase/SIAH2 E3 ubiquitin ligase pathway that regulates C/EBPδ expression and contributes to transformation of breast tumor cells. Mol Cell Biol. 2012;32:320-32 pubmed publisher

Camboni M, Hammond S, Martin L, Martin P. Induction of a regenerative microenvironment in skeletal muscle is sufficient to induce embryonal rhabdomyosarcoma in p53-deficient mice. J Pathol. 2012;226:40-9 pubmed publisher

Wang X, Wang J, Jiang X. MdmX protein is essential for Mdm2 protein-mediated p53 polyubiquitination. J Biol Chem. 2011;286:23725-34 pubmed publisher

Li Y, Zhu Z, Zhang S, Yu D, Yu H, Liu L, et al. ShRNA-targeted centromere protein A inhibits hepatocellular carcinoma growth. PLoS ONE. 2011;6:e17794 pubmed publisher

Sun Y, Klauzinska M, Lake R, Lee J, Santopietro S, Raafat A, et al. Trp53 regulates Notch 4 signaling through Mdm2. J Cell Sci. 2011;124:1067-76 pubmed publisher

Huang M, Whang P, Chodaparambil J, Pollyea D, Kusler B, Xu L, et al. Reactive oxygen species regulate nucleostemin oligomerization and protein degradation. J Biol Chem. 2011;286:11035-46 pubmed publisher

Brekman A, Singh K, Polotskaia A, Kundu N, Bargonetti J. A p53-independent role of Mdm2 in estrogen-mediated activation of breast cancer cell proliferation. Breast Cancer Res. 2011;13:R3 pubmed publisher

Sakamoto Y, Kato S, Takahashi M, Okada Y, Yasuda K, Watanabe G, et al. Contribution of autophagic cell death to p53-dependent cell death in human glioblastoma cell line SF126. Cancer Sci. 2011;102:799-807 pubmed publisher

Chu Y, Yang X. SUMO E3 ligase activity of TRIM proteins. Oncogene. 2011;30:1108-16 pubmed publisher

Xia M, Knezevic D, Vassilev L. p21 does not protect cancer cells from apoptosis induced by nongenotoxic p53 activation. Oncogene. 2011;30:346-55 pubmed publisher

Gilmore Hebert M, Ramabhadran R, Stern D. Interactions of ErbB4 and Kap1 connect the growth factor and DNA damage response pathways. Mol Cancer Res. 2010;8:1388-98 pubmed publisher

Thompson T, Andreeff M, Studzinski G, Vassilev L. 1,25-dihydroxyvitamin D3 enhances the apoptotic activity of MDM2 antagonist nutlin-3a in acute myeloid leukemia cells expressing wild-type p53. Mol Cancer Ther. 2010;9:1158-68 pubmed publisher

Soucek K, Gajduskova P, Brazdova M, Hýzd alová M, Kočí L, Vydra D, et al. Fetal colon cell line FHC exhibits tumorigenic phenotype, complex karyotype, and TP53 gene mutation. Cancer Genet Cytogenet. 2010;197:107-16 pubmed publisher

Huang B, Vassilev L. Reduced transcriptional activity in the p53 pathway of senescent cells revealed by the MDM2 antagonist nutlin-3. Aging (Albany NY). 2009;1:845-54 pubmed

Sato K, Kusama Y, Tategu M, Yoshida K. FBXL16 is a novel E2F1-regulated gene commonly upregulated in p16INK4A- and p14ARF-silenced HeLa cells. Int J Oncol. 2010;36:479-90 pubmed

Bork U, Lee W, Kuchler A, Dittmar T, Thevenod F. Cadmium-induced DNA damage triggers G(2)/M arrest via chk1/2 and cdc2 in p53-deficient kidney proximal tubule cells. Am J Physiol Renal Physiol. 2010;298:F255-65 pubmed publisher

Faustrup H, Bekker Jensen S, Bartek J, Lukas J, Mailand N. USP7 counteracts SCFbetaTrCP- but not APCCdh1-mediated proteolysis of Claspin. J Cell Biol. 2009;184:13-9 pubmed publisher

Fernandez Ranvier G, Khanafshar E, Tacha D, Wong M, Kebebew E, Duh Q, et al. Defining a molecular phenotype for benign and malignant parathyroid tumors. Cancer. 2009;115:334-44 pubmed publisher

Ofir Rosenfeld Y, Boggs K, Michael D, Kastan M, Oren M. Mdm2 regulates p53 mRNA translation through inhibitory interactions with ribosomal protein L26. Mol Cell. 2008;32:180-9 pubmed publisher

Warnock L, Knox A, Mee T, Raines S, Milner J. Influence of tetramerisation on site-specific post-translational modifications of p53: comparison of human and murine p53 tumor suppressor protein. Cancer Biol Ther. 2008;7:1481-9 pubmed

Xie P, Tian C, An L, Nie J, Lu K, Xing G, et al. Histone methyltransferase protein SETD2 interacts with p53 and selectively regulates its downstream genes. Cell Signal. 2008;20:1671-8 pubmed publisher

Xia M, Knezevic D, Tovar C, Huang B, Heimbrook D, Vassilev L. Elevated MDM2 boosts the apoptotic activity of p53-MDM2 binding inhibitors by facilitating MDMX degradation. Cell Cycle. 2008;7:1604-12 pubmed

Teoh N, Dan Y, Swisshelm K, Lehman S, Wright J, Haque J, et al. Defective DNA strand break repair causes chromosomal instability and accelerates liver carcinogenesis in mice. Hepatology. 2008;47:2078-88 pubmed publisher

Kim J, Song P, Jeong M, An J, Lee S, Jang S, et al. TIP60 represses transcriptional activity of p73beta via an MDM2-bridged ternary complex. J Biol Chem. 2008;283:20077-86 pubmed publisher

Rieber M, Rieber M. Mcl-1 cleavage and sustained phosphorylation of c-Jun-N-terminal kinase mediate melanoma apoptosis induced by 2-acetyl furanonaphthoquinone: roles of Bcl-2 and p53. Cancer Biol Ther. 2008;7:1206-11 pubmed

Li L, Zhou S, Chen X, Guo L, Li Z, Hu D, et al. The activation of p53 mediated by Epstein-Barr virus latent membrane protein 1 in SV40 large T-antigen transformed cells. FEBS Lett. 2008;582:755-62 pubmed publisher

Vitali R, Cesi V, Tanno B, Ferrari Amorotti G, Dominici C, Calabretta B, et al. Activation of p53-dependent responses in tumor cells treated with a PARC-interacting peptide. Biochem Biophys Res Commun. 2008;368:350-6 pubmed publisher

Warnock L, Adamson R, Lynch C, Milner J. Crosstalk between site-specific modifications on p53 and histone H3. Oncogene. 2008;27:1639-44 pubmed

Xiong L, Kou F, Yang Y, Wu J. A novel role for IGF-1R in p53-mediated apoptosis through translational modulation of the p53-Mdm2 feedback loop. J Cell Biol. 2007;178:995-1007 pubmed

Wassmann S, Wassmann K, Jung A, Velten M, Knuefermann P, Petoumenos V, et al. Induction of p53 by GKLF is essential for inhibition of proliferation of vascular smooth muscle cells. J Mol Cell Cardiol. 2007;43:301-7 pubmed

Janz M, Stühmer T, Vassilev L, Bargou R. Pharmacologic activation of p53-dependent and p53-independent apoptotic pathways in Hodgkin/Reed-Sternberg cells. Leukemia. 2007;21:772-9 pubmed

Yoon K, Zhu S, Ewing S, Smart R. Decreased survival of C/EBP beta-deficient keratinocytes is due to aberrant regulation of p53 levels and function. Oncogene. 2007;26:360-7 pubmed

Ribas J, Boix J, Meijer L. (R)-roscovitine (CYC202, Seliciclib) sensitizes SH-SY5Y neuroblastoma cells to nutlin-3-induced apoptosis. Exp Cell Res. 2006;312:2394-400 pubmed

Radhakrishnan S, Gartel A. A novel transcriptional inhibitor induces apoptosis in tumor cells and exhibits antiangiogenic activity. Cancer Res. 2006;66:3264-70 pubmed

Wadhwa R, Takano S, Kaur K, Deocaris C, Pereira Smith O, Reddel R, et al. Upregulation of mortalin/mthsp70/Grp75 contributes to human carcinogenesis. Int J Cancer. 2006;118:2973-80 pubmed

Muthusamy V, Hobbs C, Nogueira C, Cordon Cardo C, McKee P, Chin L, et al. Amplification of CDK4 and MDM2 in malignant melanoma. Genes Chromosomes Cancer. 2006;45:447-54 pubmed

Hu C, Smith S, Pang L, Sadovsky Y, Nelson D. Enhanced basal apoptosis in cultured term human cytotrophoblasts is associated with a higher expression and physical interaction of p53 and Bak. Placenta. 2006;27:978-83 pubmed

Naumann U, Huang H, Wolburg H, Wischhusen J, Weit S, Ohgaki H, et al. PCTAIRE3: a putative mediator of growth arrest and death induced by CTS-1, a dominant-positive p53-derived synthetic tumor suppressor, in human malignant glioma cells. Cancer Gene Ther. 2006;13:469-78 pubmed

Radhakrishnan S, Gierut J, Gartel A. Multiple alternate p21 transcripts are regulated by p53 in human cells. Oncogene. 2006;25:1812-5 pubmed

Rogulski K, Li Y, Rothermund K, Pu L, Watkins S, Yi F, et al. Onzin, a c-Myc-repressed target, promotes survival and transformation by modulating the Akt-Mdm2-p53 pathway. Oncogene. 2005;24:7524-41 pubmed

Stühmer T, Chatterjee M, Hildebrandt M, Herrmann P, Gollasch H, Gerecke C, et al. Nongenotoxic activation of the p53 pathway as a therapeutic strategy for multiple myeloma. Blood. 2005;106:3609-17 pubmed